title: Remyelination in vitro following protein kinase C activator-induced demyelination.
abstract: In previous work we found that mezerein, a C kinase activator, as well as basic fibroblast growth factor (FGF-2) induce demyelination and partial oligodendrocyte dedifferentiation in highly differentiated aggregating brain cell cultures. Here we show that following protein kinase C activator-induced demyelination, effective remyelination occurs. We found that mezerein or FGF-2 caused a transient increase in DNA synthesis following a pronounced decrease of the myelin markers myelin basic protein and 2',3'-cyclic nucleotide 3'-phosphohydrolase. Both oligodendrocytes and astrocytes were involved in this mitogenic response. Within 17 days after demyelination, myelin was restored to the level of the untreated controls. Transient mitotic activity was indispensable for remyelination. The present results suggest that myelinating oligodendrocytes retain the capacity to reenter the cell cycle, and that this plasticity is important for the regeneration of the oligodendrocyte lineage and remyelination. Although it cannot be excluded that a quiescent population of oligodendrocyte precursor cells was present in the aggregates and able to proliferate, differentiate and remyelinate, we could not find evidence supporting this view.
authors.affiliation: Institute of Physiology, UNIL, Lausanne, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Pouly
authors.forename: J M
authors.initials: JM
authors.lastname: Matthieu
authors.forename: P
authors.initials: P
authors.lastname: Honegger
mesh_terms: D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases / Q000378:metabolism; D000818:Animals; D000077214:Becaplermin; D015415:Biomarkers; D001921:Brain / Q000473:pathology / Q000503:physiopathology*; D002455:Cell Division / Q000502:physiology; D003561:Cytarabine / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000503:physiopathology; D004224:Diterpenes; D004789:Enzyme Activation / Q000502:physiology*; D005333:Fetus; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D066298:In Vitro Techniques; D008938:Mitosis / Q000502:physiology; D004676:Myelin Basic Protein / Q000037:antagonists & inhibitors; D009186:Myelin Sheath / Q000187:drug effects / Q000502:physiology*; D009836:Oligodendroglia / Q000473:pathology / Q000502:physiology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011493:Protein Kinase C / Q000378:metabolism*; D020574:Proto-Oncogene Proteins c-sis; D051381:Rats; D013729:Terpenes / Q000494:pharmacology*
chemical_list: D015415:Biomarkers; D004224:Diterpenes; D004676:Myelin Basic Protein; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D013729:Terpenes; D003561:Cytarabine; D016222:Fibroblast Growth Factor 2; D000077214:Becaplermin; C011309:mezerein; D004247:DNA; D011493:Protein Kinase C; D015087:2',3'-Cyclic-Nucleotide Phosphodiesterases; C039809:2',3'-cyclic nucleotide 2'-phosphodiesterase